August 1, 2001Hypertension
Endogenous Natriuretic Peptides Participate in Renal and Humoral Actions of Acute Vasopeptidase Inhibition in Experimental Mild Heart Failure
Why the study?
Does acute vasopeptidase inhibition with omapatrilat improve renal and humoral responses compared to ACE inhibition in a canine model of mild heart failure?
Population
Canine model of mild heart failure produced by ventricular pacing at 180 bpm for 10 days (n=16)
Comparison
Acute vasopeptidase inhibition with omapatrilat… vs Acute ACE inhibition alone with fosinoprilat (n=5)
Design
Preclinical
Follow-up
Acute
Authors
Discussion
Loading...
Member takes
Implication
Supports testing vasopeptidase inhibition in experimental HF; leaves open translation to patients.
Structured PICO
Does acute vasopeptidase inhibition with omapatrilat improve renal and humoral responses compared to ACE inhibition in a canine model of mild heart failure?
P
Population
Canine model of mild heart failure produced by ventricular pacing at 180 bpm for 10 days (n=16)
I
Intervention
Acute vasopeptidase inhibition with omapatrilat (n=6) or omapatrilat combined with intrarenal administration of the natriuretic peptide receptor antagonist HS-142-1 (n=5)
C
Comparator
Acute ACE inhibition alone with fosinoprilat (n=5)
O
Outcome
Renal and humoral actions including natriuretic response, plasma cGMP, ANP, BNP, urinary cGMP, urinary ANP excretion, and glomerular filtration ratesurrogate
Acute vasopeptidase inhibition with omapatrilat provides greater renal and humoral benefits than ACE inhibition alone in experimental mild heart failure, mediated by the natriuretic peptide system.
Cite This Study
Chen et al. (2001) studied this question.